AIM ImmunoTech (AIM) Competitors $0.09 -0.03 (-22.34%) As of 04/4/2025 This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AIM vs. CLNN, DARE, CASI, CARA, QTTB, GBIO, TPST, CGTX, PASG, and CYTHShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Clene (CLNN), Daré Bioscience (DARE), CASI Pharmaceuticals (CASI), Cara Therapeutics (CARA), Q32 Bio (QTTB), Generation Bio (GBIO), Tempest Therapeutics (TPST), Cognition Therapeutics (CGTX), Passage Bio (PASG), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Clene Daré Bioscience CASI Pharmaceuticals Cara Therapeutics Q32 Bio Generation Bio Tempest Therapeutics Cognition Therapeutics Passage Bio Cyclo Therapeutics AIM ImmunoTech (NYSE:AIM) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability. Is AIM or CLNN more profitable? Clene has a net margin of -8,556.77% compared to AIM ImmunoTech's net margin of -12,594.21%. AIM ImmunoTech's return on equity of -421.73% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Clene -8,556.77%-1,106.30%-85.11% Do insiders & institutionals have more ownership in AIM or CLNN? 12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 25.1% of Clene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, AIM or CLNN? AIM ImmunoTech has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$170K38.87-$28.96M-$0.31-0.29Clene$342K79.68-$49.50M-$5.75-0.55 Which has more risk and volatility, AIM or CLNN? AIM ImmunoTech has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Do analysts prefer AIM or CLNN? AIM ImmunoTech presently has a consensus target price of $2.75, indicating a potential upside of 2,908.75%. Clene has a consensus target price of $50.20, indicating a potential upside of 1,483.60%. Given AIM ImmunoTech's higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than Clene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to AIM or CLNN? In the previous week, Clene had 3 more articles in the media than AIM ImmunoTech. MarketBeat recorded 4 mentions for Clene and 1 mentions for AIM ImmunoTech. AIM ImmunoTech's average media sentiment score of 0.08 beat Clene's score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AIM ImmunoTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor AIM or CLNN? Clene received 23 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 83.10% of users gave AIM ImmunoTech an outperform vote while only 81.19% of users gave Clene an outperform vote. CompanyUnderperformOutperformAIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90%CleneOutperform Votes8281.19% Underperform Votes1918.81% SummaryClene beats AIM ImmunoTech on 11 of the 19 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.61M$2.93B$5.41B$18.87BDividend YieldN/A1.91%5.44%4.15%P/E Ratio-0.1930.4322.1832.40Price / Sales38.87478.52397.3128.58Price / CashN/A168.6838.2017.53Price / Book0.463.786.834.44Net Income-$28.96M-$72.06M$3.20B$1.02B7 Day PerformanceN/A11.17%5.76%3.35%1 Month PerformanceN/A-4.87%-4.32%-5.48%1 Year PerformanceN/A-18.74%17.88%4.28% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.8867 of 5 stars$0.09-22.3%$2.75+2,908.8%-78.7%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCLNNClene2.2436 of 5 stars$3.08+1.7%$55.25+1,693.8%-53.0%$26.05M$342,000.00-0.58100Analyst ForecastNews CoverageGap UpDAREDaré Bioscience1.6614 of 5 stars$2.93-0.3%$24.00+719.1%-12.6%$25.93M$9,784.00-4.9630CASICASI Pharmaceuticals4.0461 of 5 stars$2.10+7.6%$4.00+90.7%-17.2%$25.80M$28.54M-0.94180Gap UpCARACara Therapeutics3.24 of 5 stars$5.55+13.3%$27.84+401.6%N/A$25.39M$7.14M-0.2680Analyst ForecastGap DownQTTBQ32 Bio1.7497 of 5 stars$1.92-7.7%$24.71+1,187.2%-93.0%$25.37M$-6,651,000.00-0.1339GBIOGeneration Bio2.7689 of 5 stars$0.37-3.4%$7.33+1,860.8%-85.9%$25.06M$19.89M-0.17150Gap DownHigh Trading VolumeTPSTTempest Therapeutics2.3083 of 5 stars$6.96+11.9%$30.00+331.0%-82.0%$24.49MN/A-4.5520CGTXCognition Therapeutics2.5443 of 5 stars$0.39+11.6%$7.13+1,708.4%-77.8%$24.42MN/A-0.4120PASGPassage Bio2.4952 of 5 stars$0.38+5.7%$7.50+1,857.7%-73.8%$23.81MN/A-0.33130CYTHCyclo Therapeutics2.7432 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809 Related Companies and Tools Related Companies CLNN Alternatives DARE Alternatives CASI Alternatives CARA Alternatives QTTB Alternatives GBIO Alternatives TPST Alternatives CGTX Alternatives PASG Alternatives CYTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AIM Stock Free AIM Stock Alerts